Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • Arthritis drug could...

    Arthritis drug could provide relief for lichen planus skin rash in future, finds study

    Written by Hina Zahid Published On 2019-09-27T19:05:33+05:30  |  Updated On 27 Sept 2019 7:05 PM IST
    Arthritis drug could provide relief for lichen planus skin rash in future, finds study

    Lichen planus is an inflammatory skin disease that’s both frustrating and painful for patients trying to keep their quality of life. The patients have to face constant itchy, painful bumps, scaly arms and legs, and damaged nails. It is most likely triggered by an underlying immune disorder, experts say, can also lead to significant scarring.


    Dermatologists at Michigan Medicine have recently discovered more about how lichen planus develops. Their findings suggest that an arthritis drug could be used to treat the rash in the future. The new research has been published in Science Translational Medicine.


    “We found the pathway behind the immune response that sparks lichen planus, which has a marked impact on the quality of life,” says senior author Johann E. Gudjonsson, M.D., an associate professor of dermatology at U-M. Gudjonsson is also director of U-M’s new Skin Biology and Diseases Resource-based Center, funded by the National Institutes of Health.


    “Clinically, lichen planus can resemble other autoimmune diseases in its manifestations, and we believe that lichen planus is likely also an autoimmune disease,” Gudjonsson says.


    But because not much is known yet about the pathogenesis of lichen planus, Gudjonsson notes comparison against other inflammatory diseases is lacking.


    Gudjonsson explains why improving care for lichen planus has proven difficult, and how his team is paving the path toward future treatments.


    Why do you call lichen planus a diagnosis with a major effect on the quality of life?


    Gudjonsson: Lichen planus is a disease with many different clinical forms and often variable appearance and can involve the skin, hair, nails and mucosal areas of the mouth and genitals. It affects around 1% of the general population.


    On the skin, it can leave behind irregular dark patches, loss of hair and loss or permanent scarring of nails. In the vaginal areas and mouth, it can cause painful sores, and many people are unable to properly eat. Over time, the lesions in the mouth and genitalia can lead to significant scarring.


    In addition, lichen planus is associated with an increased risk of cancer in longstanding lesions, a devastating complication of this disease.


    Why has it been difficult to find viable treatment options for lichen planus?


    Gudjonsson: I believe that the major reason for this is that the disease hasn’t been much studied and markedly lags behind other skin diseases in terms of resources that have been devoted for research. That’s also why there have been no major clinical trials to identify treatments for this disease, and most of the treatments currently used to treat lichen planus are “borrowed” from other disease fields.


    How did you identify a potential future treatment for lichen planus in your new research publication?


    Gudjonsson: We used tissue samples from about 40 patients with an established diagnosis of lichen planus to identify the key inflammatory pathways involved. We then showed in a skin model system that the disease is primarily mediated by an inflammatory mediator called interferon-gamma and signals through a specific inflammatory signaling pathway that utilizes the signaling molecules JAK2, and STAT1.


    As there are existing treatments currently approved for arthritis that target this same pathway, we provide some evidence in our skin model system that drugs targeting this pathway are likely to be effective in lichen planus.


    What further research is needed?


    Gudjonsson: Significant work still remains to be done. While our data suggests that JAK inhibitors would be effective in lichen planus, prospective randomized clinical trials are needed before we will know how effective and safe they would be in treating lichen planus.


    For more details click on the link: DOI: 10.1126/scitranslmed.aav7561
    Arthritis treatmentdamaged nailsdark patchesJohann E Gudjonssonlichen planusloss of hairNational Institutes of Healthpainful bumpsScience Translational Medicineskin diseaseskin rash

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Hina Zahid
    Hina Zahid
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok